RLMD
Price:
$6.65
Market Cap:
$487.67M
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology firm, concentrating its efforts on developing various therapeutic solutions for ailments affecting the central nervous system (CNS) and other disorders. The company's primary drug candidate is Esmethadone (also known as d-methadone, dextromethadone, or REL-1017), a novel chemical compound. This N-methyl-D-aspartate receptor antagonist is currently undergoing Phase 3 clinical trials, investigating its efficacy as both a supplementary and standalone treatment for major depressive disorder in adult patients. Founded in 2004, the enterprise maintains its corporate headquarters in Coral Gables, Florida.
Industry
Biotechnology
IPO Date
2014-06-20
Stock Exchange
NASDAQ
Ticker
RLMD
According to Relmada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 18.26. This represents a change of 83.28% compared to the average of 9.96 of the last 4 quarters.
The mean historical Current Ratio of Relmada Therapeutics, Inc. over the last ten years is 14.98. The current 18.26 Current Ratio has changed 12.08% with respect to the historical average. Over the past ten years (40 quarters), RLMD's Current Ratio was at its highest in in the December 2019 quarter at 80.21. The Current Ratio was at its lowest in in the September 2018 quarter at 0.18.
Average
14.98
Median
8.68
Minimum
0.46
Maximum
80.21
Discovering the peaks and valleys of Relmada Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.99%
Maximum Annual Current Ratio = 80.21
Minimum Annual Increase = -88.32%
Minimum Annual Current Ratio = 0.46
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 14.62 | 228.44% |
| 2024 | 4.45 | -44.35% |
| 2023 | 8.00 | -34.78% |
| 2022 | 12.26 | -17.31% |
| 2021 | 14.83 | 58.26% |
| 2020 | 9.37 | -88.32% |
| 2019 | 80.21 | 1.99% |
| 2019 | 3.83 | 726.13% |
| 2018 | 0.46 | -74.21% |
| 2017 | 1.80 | -40.82% |
The current Current Ratio of Relmada Therapeutics, Inc. (RLMD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
9.02
5-year avg
10.83
10-year avg
14.98
Relmada Therapeutics, Inc.’s Current Ratio is greater than Acrivon Therapeutics, Inc. Common Stock (8.98), greater than PMV Pharmaceuticals, Inc. (11.14), greater than Immunic, Inc. (4.92), greater than TScan Therapeutics, Inc. (6.65), greater than Vaxart, Inc. (1.71), greater than Lite Strategy, Inc. (11.53), greater than Fortress Biotech, Inc. (2.86), greater than Repare Therapeutics Inc. (10.71), greater than Cibus, Inc. (2.37), greater than Adicet Bio, Inc. (7.65),
| Company | Current Ratio | Market cap |
|---|---|---|
| 8.98 | $46.70M | |
| 11.14 | $59.20M | |
| 4.92 | $136.78M | |
| 6.65 | $55.71M | |
| 1.71 | $135.55M | |
| 11.53 | $25.22M | |
| 2.86 | $92.02M | |
| 10.71 | $114.24M | |
| 2.37 | $55.95M | |
| 7.65 | $75.25M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relmada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Relmada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Relmada Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Relmada Therapeutics, Inc. (RLMD)?
What is the highest Current Ratio for Relmada Therapeutics, Inc. (RLMD)?
What is the 3-year average Current Ratio for Relmada Therapeutics, Inc. (RLMD)?
What is the 5-year average Current Ratio for Relmada Therapeutics, Inc. (RLMD)?
How does the current Current Ratio for Relmada Therapeutics, Inc. (RLMD) compare to its historical average?